米国の変形性関節症向け注射剤市場規模、シェア、動向分析レポート：注射剤タイプ別、解剖学別、最終用途別、セグメント別予測、2024年～2030年

米国の変形性関節症向け注射剤市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国の変形性関節症向け注射剤市場規模は2030年までに63億米ドルに達すると予測され、2024年から2030年までのCAGRは6.8%で拡大する見込みです。

同市場は主に、変形性関節症の有病率の増加と個別化医療に対する高い需要が牽引しています。さらに、製薬会社や研究・学術機関は、国内のOAに対する個別化治療や細胞ベースの治療法の開発に関与しています。例えば、2023年5月、UCI Health社は、軽度から中等度の変形性膝関節症患者の筋萎縮を対象とした、細胞由来の注射治療薬IMMO1-STEMのヒト初臨床試験を発表しました。

変形性膝関節症に罹患しやすい老年人口の増加が市場の成長を促進しています。2023年5月のNCBIの報告によると、急速な高齢化と肥満が相まって、OAを患う人の数は2030年までに2倍以上の6,700万人になると予想されています。さらに、OA症例の50％以上が65歳以上の年齢層で発生すると予想されています。2024年3月にCDCが支援したOAAAの調査によると、OAを患う人の約45％が65歳以上であり、全症例の88％が45歳以上の年齢層で発生しています。膝関節OAの年間発症率は、国内では55歳から64歳が最も高いです。このような老人人口の高いリスクは、作業効率を低下させ、国内での疾病負担を増加させることにより、全体的な生産性に影響を及ぼしています。

OAの症状を管理し、その構造的な進行を予防するために、主な製薬会社や研究機関は、新薬、特に疾患修飾性OA治療薬の開発のための研究開発活動に積極的に取り組んでいます。例えば、2024年1月、BioSenic社は、国際変形性関節症学会（OARSI）世界会議2024において、JTA-004の第3相試験の事後解析データを共有する計画を発表しました。JTA-004は膝関節OAに対する革新的なIA治療薬であり、本試験では、重度の炎症性サブタイプの膝関節OAに対して、治験薬の単回注射が安全かつ有効であることが示されました。

さらに、OAに対する新しい治療法の開発にも研究機関や学術機関が関わっています。例えば、2023年3月、Science Translational Medicineの報告書GP130によると、ある治験薬は炎症を破壊し、疼痛とこわばりを管理することができます。この薬剤は今後、臨床試験の初期段階で試験される予定です。さらに、2021年12月、Kolon TissueGene, Inc.は、米国FDAが股関節OAにおけるTG-Cの第2相臨床試験の開始を許可したと発表しました。この試験では、調査期間中の疼痛とQOLの改善が評価されます。

米国の変形性関節症向け注射剤市場レポート・ハイライト

• 2023年、ヒアルロン酸（HA）注射分野が米国市場を独占しました。変形性関節症に対するHA注射療法の最近の進歩により、HAベースのハイドロゲル治療薬が注目されています。
• 変形性膝関節症分野は、2023年に市場で最大のシェアを占めました。この疾患の有病率の上昇は、高齢者人口の生活の質を向上させ、障害率を減少させるために、高齢者人口における変形性膝関節症の予防と治療の必要性を高めると予想されます。
• 小売薬局セグメントは、予測期間中に最も速いCAGRを記録すると予測されています。小売薬局はメーカーとヘルスケアプロバイダーの仲介役として、変形性膝関節症の注射剤を大量に購入し、要求されるまで保管します。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の変形性関節症向け注射剤市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 米国の変形性関節症向け注射剤市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • 価格分析

第4章 米国の変形性関節症向け注射剤市場：注射剤タイプの推定・動向分析

• 米国の変形性関節症向け注射剤市場：注射剤タイプダッシュボード
• 米国の変形性関節症向け注射剤市場：注射剤タイプの変動分析
• 注射タイプ別収益
• ヒアルロン酸注射
• コルチコステロイド注射
• 多血小板血漿（PRP）注射
• 胎盤組織マトリックス（PTM）注射
• アセチルサリチル酸（ASA）注射
• その他

第5章 米国の変形性関節症向け注射剤市場：解剖学の推定・動向分析

• 米国の変形性関節症向け注射剤市場：解剖ダッシュボード
• 米国の変形性関節症向け注射剤市場：解剖学の変動分析
• 解剖学、収益
• 変形性膝関節症
• 変形性股関節症
• 手の変形性関節症
• その他

第6章 米国の変形性関節症向け注射剤市場：最終用途の推定・動向分析

• 米国の変形性関節症向け注射剤市場：最終用途ダッシュボード
• 米国の変形性関節症向け注射剤市場：最終用途の変動分析
• 最終用途別、収益
• 病院薬局
• 小売薬局
• その他

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要ディストリビューターおよびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023年
• 企業プロファイル
  • Anika Therapeutics, Inc.
  • Bioventus.
  • Ferring Pharmaceuticals Inc.
  • Sanofi SA
  • Flexion Therapeutics, Inc.
  • Zimmer Biomet
  • Arthrex, Inc.
  • Royal Biologics
  • Teva Pharmaceutical Industries Ltd.

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviation
• Table 3 Pipeline analysis, osteoarthritis injectables
• Table 4 Pricing of key injectable drugs/therapies
• Table 5 U.S. osteoarthritis injectables market revenue estimates and forecast, by injection type, 2018 - 2030 (USD Million)
• Table 6 U.S. osteoarthritis injectables market revenue estimates and forecast, by anatomy, 2018 - 2030 (USD Million)
• Table 7 U.S. osteoarthritis injectables market revenue estimates and forecast, by end use, 2018 - 2030 (USD Million)
• Table 8 Company market share, 2023
• Table 9 List of players adopting acquisition strategy
• Table 10 Key companies undergoing partnership & collaborations.
• Table 11 Key companies receiving approvals.
• Table 12 Key companies undertaking other activities.

List of Figures

• Fig. 1 U.S. osteoarthritis injectables market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Value chain based sizing & forecasting
• Fig. 6 QFD modelling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Injection type and anatomy segment snapshot
• Fig. 10 End-use segment snapshot
• Fig. 11 Competitive landscape snapshot
• Fig. 12 Parent market (USD billion)
• Fig. 13 U.S. osteoarthritis injectables market dynamics
• Fig. 14 Prevalence of osteoarthritis in the U.S., by type
• Fig. 15 U.S. population aged 65 and above, by years (Million)
• Fig. 16 U.S. pharmaceuticals registration details
• Fig. 17 U.S. drug pricing
• Fig. 18 U.S. osteoarthritis injectables market: PORTER's analysis
• Fig. 19 U.S. osteoarthritis injectables market: PESTLE analysis
• Fig. 20 U.S. osteoarthritis injectables market: Injection type outlook and key takeaways
• Fig. 21 U.S. osteoarthritis injectables market: Injection type movement analysis
• Fig. 22 Corticosteroid injections market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Hyaluronic acid injections market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Platelet-rich Plasma (PRP) injections market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Placental Tissue Matrix (PTM) injections market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Acetylsalicylic Acid (ASA) injections market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 U.S. osteoarthritis injectables market: Anatomy outlook and key takeaways
• Fig. 29 U.S. osteoarthritis injectables market: Anatomy movement analysis
• Fig. 30 Knee osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Hip osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Hand osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 U.S. osteoarthritis injectables market: End-use outlook and key takeaways
• Fig. 35 U.S. osteoarthritis injectables market: End-use movement analysis
• Fig. 36 Hospitals pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Others market estimates and forecast, 2018 - 2030 (USD Million)

U.S. Osteoarthritis Injectables Market Growth & Trends:

The U.S. osteoarthritis injectables market size is anticipated to reach USD 6.30 billion by 2030 and is expected to expand at a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing prevalence of osteoarthritis and high demand for personalized medicine. Moreover, pharmaceutical companies and research & academic institutes are involved in the development of personalized treatment and cell-based therapies for OA in the country. For instance, in May 2023, UCI Health announced the first-in-human clinical trial of its IMMO1-STEM, a cell-derived injectable treatment, to target muscle atrophy in patients with mild to moderate knee osteoarthritis.

Growing geriatric population susceptible to osteoarthritis fuels the growth of the market. According to the NCBI report in May 2023, a rapidly aging population coupled with obesity is expected to more than double the number of people suffering from OA to 67 million by 2030.Moreover, it is expected that more than 50% of OA cases are expected to occur in the age group of 65 and above.According to an OAAA study supported by CDC in March 2024, around 45% of people having OA are 65 & above and 88% of the total cases occur in the age group of 45 & above. The annual incidence of knee OA is highest among people aged 55 to 64 in the country. Such a high risk for geriatric population is affecting overall productivity by reducing work efficiency and increasing the disease burden in the country.

Increase in R&D activities for injectable drug development is boosting the market growth.To manage OA symptoms and prevent its structural progression, key pharmaceutical companies and research institutes are actively involved in R&D activities for the development of novel drugs, especially disease-modifying OA drugs. For instance, in January 2024, BioSenic announced its plans to share the data of post hoc analysis of the phase 3 study of JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024. JTA-004 is an innovative IA treatment for knee OA, and the study showed that a single injection of an investigational drug is safe and effective for the treatment of severe inflammatory subtypes of knee OA.

Furthermore, research and academic institutes are involved in the development of novel treatment options for OA. For instance, in March 2023, according to Science Translational Medicine report GP130, an investigational drug can disrupt inflammation and manage pain & stiffness. The drug will be tested in the upcoming initial phases of clinical trials. Moreover, in December 2021, Kolon TissueGene, Inc. announced that the U.S. FDA allowed it to initiate a Phase 2 clinical trial of TG-C in OA of the hip. The study will assess the pain and quality-of-life improvements during the investigation period.

U.S. Osteoarthritis Injectables Market Report Highlights:

• In 2023, Hyaluronic Acid (HA) injections segment dominated the U.S. market, owing to recent advancements in HA injection therapy for osteoarthritis focus on HA-based hydrogel therapeutics.
• Knee osteoarthritis segment held the largest share of the market in 2023.The rising prevalence of the condition is expected to boost the need for the prevention and treatment of knee osteoarthritis in the older population to improve quality of life and decrease disability rates in the elderly population.
• The retail pharmacies segment is anticipated to witness the fastest CAGR over the forecast period. Retail pharmacies serve as intermediaries between manufacturers and healthcare providers, purchasing osteoarthritis injectables in bulk and storing them until requested.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Injection Type
  • 1.2.2. End-use
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Injection Type
  • 2.2.2. End-use
• 2.3. Competitive Insights

Chapter 3. U.S. Osteoarthritis Injectables Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of osteoarthritis
    • 3.2.1.2. Growing geriatric population susceptible to osteoarthritis
    • 3.2.1.3. Increase in R&D activities for injectable drug development
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Adoption of other treatment options
    • 3.2.2.2. High cost of treatment
• 3.3. U.S. Osteoarthritis Injectables Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Pricing Analysis
  • 3.3.3. Pricing Analysis

Chapter 4. U.S. Osteoarthritis Injectables Market: Injection Type Estimates & Trend Analysis

• 4.1. U.S. Osteoarthritis Injectables Market: Injection Type Dashboard
• 4.2. U.S. Osteoarthritis Injectables Market: Injection Type Movement Analysis
• 4.3. U.S. Osteoarthritis Injectables Market Estimates and Forecasts, By Injection Type, Revenue (USD Million)
• 4.4. Hyaluronic Acid Injections
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Corticosteroid Injections
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Platelet-rich Plasma (PRP) Injections
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Placental Tissue Matrix (PTM) Injections
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Acetylsalicylic Acid (ASA) Injections
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Osteoarthritis Injectables Market: Anatomy Estimates & Trend Analysis

• 5.1. U.S. Osteoarthritis Injectables Market: Anatomy Dashboard
• 5.2. U.S. Osteoarthritis Injectables Market: Anatomy Movement Analysis
• 5.3. U.S. Osteoarthritis Injectables Market Estimates and Forecasts, By Anatomy, Revenue (USD Million)
• 5.4. Knee Osteoarthritis
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Hip Osteoarthritis
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Hand Osteoarthritis
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Osteoarthritis Injectables Market: End-use Estimates & Trend Analysis

• 6.1. U.S. Osteoarthritis Injectables Market: End-use Dashboard
• 6.2. U.S. Osteoarthritis Injectables Market: End-use Movement Analysis
• 6.3. U.S. Osteoarthritis Injectables Market Estimates and Forecasts, By End-use, Revenue (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
• 7.4. Company Profiles
  • 7.4.1. Anika Therapeutics, Inc.
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Bioventus.
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Ferring Pharmaceuticals Inc.
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Sanofi S.A.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Flexion Therapeutics, Inc.
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Zimmer Biomet
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Arthrex, Inc.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Royal Biologics
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Teva Pharmaceutical Industries Ltd.
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives